Acurx Pharmaceuticals, Inc. (ACXP) Aktienanalyse

Unternehmensübersicht

Acurx Pharmaceuticals, Inc. operates within the healthcare sector as a clinical-stage biopharmaceutical company focused on the United States market. The firm's primary business involves the development of antibiotics designed to treat bacterial infections, utilizing a novel mechanism of action known as ibezapolstat. This lead candidate specifically targets the polymerase IIIC enzyme and is currently progressing through Phase 2b clinical trials. With a total market capitalization of 8,450,000 US dollars and an employee count of four, the company represents a highly specialized micro-cap entity. The minimal employee base combined with a market cap under ten million dollars indicates that the enterprise is in an early-stage development phase where capital allocation is directed almost exclusively toward clinical research rather than commercial operations or large-scale manufacturing. These valuation metrics reflect the high-risk, high-reward profile typical of biotechnology firms that have not yet achieved commercial revenue generation.

Finanzielle Gesundheit

The reported revenue for the trailing twelve months is not available, while the net income stands at a loss of 7,966,538 US dollars and EBITDA is not available. The substantial negative net income relative to the lack of recorded revenue highlights a cost structure dominated by clinical trial expenses and operational burn rates typical of pre-commercial biotech ventures. Free cash flow is reported at a negative 4,291,853 US dollars, indicating that the company is consuming cash reserves to fund its development pipeline rather than generating operating liquidity. This negative cash flow position necessitates reliance on existing capital or external financing to sustain operations until the lead candidate reaches market approval. The gross margin, operating margin, and profit margin are all recorded at 0.0%, which is consistent with the company's stage of development where revenue is negligible and costs are incurred before any sales occur. The company holds a cash balance of 7,560,000 US dollars against zero debt, creating a conservative balance sheet with no leverage obligations. This zero-debt position is further evidenced by a debt-to-equity ratio that is not applicable, suggesting the firm has no fixed financial obligations that could threaten solvency during volatile development periods. The current ratio stands at 3.18, indicating that the company possesses sufficient short-term liquid assets to cover its current liabilities more than three times over. Return on equity is calculated at -270.8% and return on assets at -87.6%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than profits. These negative return figures are characteristic of early-stage companies investing heavily in research and development without yet realizing commercial returns.

Bewertungsanalyse

The trailing twelve months P/E ratio is not available due to the absence of positive earnings, while the forward P/E is listed as negative 1.35. The negative forward P/E implies that analysts or data providers project continued losses or that the valuation model is adjusted for a company with no current profitability. The price-to-book ratio is 1.32, suggesting that the market values the company at 32% above its book value, likely reflecting the intangible value of the intellectual property and the potential of the ibezapolstat pipeline. The price-to-sales ratio and EV/EBITDA are both not available, meaning traditional revenue-based or enterprise value metrics cannot be applied to a firm with negligible sales and no earnings. The stock's trading range over the past year spans from a 52-week low of 1,33 US dollars to a high of 21,00 US dollars. At the time of the latest data, the share price sits significantly below the 52-week high, reflecting the speculative nature of the asset and the risks associated with late-stage clinical trials. The beta value is -1.92, an anomalous and highly negative figure that indicates the stock price moves inversely to the broader market with extreme volatility. Such a negative beta suggests that the stock's performance is decoupled from general market movements, potentially driven by specific biotech sector dynamics or data releases rather than macroeconomic trends.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both not available due to the lack of historical financial data required for calculation. The absence of these growth rates means that traditional growth investing metrics cannot be applied, as the company has not yet generated consistent commercial revenue to measure expansion. Since the company does not pay a dividend, the dividend yield is not available and the payout ratio is 0.0%. This 0.0% payout ratio confirms that the firm retains all available capital to reinvest into its research and development activities rather than distributing income to shareholders. Consequently, the company's growth profile is entirely dependent on the success of its clinical trials and the eventual commercialization of its antibiotic candidates rather than organic sales growth or income generation. The overall financial profile presents a classic early-stage biotechnology scenario where capital preservation is prioritized over income distribution, with all resources channeled toward advancing the lead candidate through Phase 2b trials.